Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 16/20 | 0.66 |
| ▸ | PLK3 | Q9H4B4 | 14/20 | 0.66 |
| ▸ | NEK2 | P51955 | 3/20 | 0.66 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.66 |
| ▸ | NUAK1 | O60285 | 2/20 | 0.66 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.66 |
| ▸ | PIM1 | P11309 | 2/20 | 0.66 |
| ▸ | KDR | P35968 | 2/20 | 0.66 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.57 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14029689 | 0.93 | PLK1 (0.58) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4403045 | 0.92 | PLK1 (0.70) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL14029504 | 0.90 | PLK1 (0.74) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL14029724 | 0.87 | PLK1 (0.62) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL14029473 | 0.85 | PLK1 (0.67) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4404140 | 0.85 | PLK1 (0.61) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4401761 | 0.84 | PLK1 (0.65) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL14029456 | 0.84 | PLK1 (0.65) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4401438 | 0.84 | PLK1 (0.73) | PLK1PLK3NEK2PIK3CDNUAK1 | |
| SCHEMBL4412251 | 0.84 | PLK1 (0.64) | PLK1PLK3NEK2PIK3CDNUAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | SMITHKLINE BEECHAM CORPORATION | 2008-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080249301-A1 | Regioselective Process for Preparing Benzimidazole Thiophenes | CYP3A4, CYP2C19, CYP2B6 | PLK1 1718/4885PLK3 2097/4885NEK2 1915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.